Physician profile
Michele Chen
NPI 1063867695
$888.16
in general payments reported to CMS, 2019-2025
15 companies · $22.23 in 2025
The $22.23 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $124 · 2022: $211 · 2023: $333 · 2024: $199 · 2025: $22.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $554.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $554.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $189.07 | 2021-2022 | |
| Merz North America, INC. | $157.78 | 2024 | |
| Puma Biotechnology, INC. | $128.48 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $68.76 | 2023 | Calquence, Enhertu, Saphnelo |
| Genzyme Corporation | $60.20 | 2023-2024 | |
| Seagen INC. | $51.99 | 2023 | Tukysa |
| Abbvie INC. | $38.72 | 2022-2025 | |
| Pharmaessentia USA Corporation | $37.37 | 2023 | Besremi |
| Ipsen Biopharmaceuticals, INC | $25.86 | 2023 | Tazverik |
| Daiichi Sankyo INC. | $25.84 | 2023 | Injectafer |
| Foundation Medicine, INC. | $25.55 | 2023 | |
| Lundbeck LLC | $22.02 | 2023 | Vyepti |
| Glaxosmithkline, LLC. | $21.38 | 2023 | Zejula |
| E.R. Squibb & Sons, L.L.C. | $18.18 | 2023 | Opdualag |
| Takeda Pharmaceuticals U.S.A., INC. | $16.96 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.